Stock A085660 CHABIOTECH CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Chabiotech Co.,Ltd.

Equities

A085660

KR7085660009

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
17,000 KRW +3.91% Intraday chart for Chabiotech Co.,Ltd. -0.35% -13.22%
May. 16 Chabiotech Co.,Ltd. announced that it has received KRW 74.799682128 billion in funding from a group of investors CI
May. 08 Chabiotech Co.,Ltd. announced that it expects to receive KRW 74.799682128 billion in funding from a group of investors CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
CHA Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
CHA Biotech : Unit Signs Contract with Sartorius for Viral Vectors Process Technology
MT
Astellas Institute for Regenerative Medicine acquired remaining 50% stake in Stem Cell & Regenerative Medicine International, Inc from CHA Biotech Co., Ltd. for $46.7 million.
CI
Chabiotech To Divest Biotechnology And Medicine And Medical Supplies
CI
Sorrento Therapeutics to Form Joint Venture with CHA Biotech Co
CI
Sorrento Therapeutics, Inc. to Form Joint Venture with CHA Biotech Co., Ltd. to Develop and Commercialize Natural Killer Cell Therapies
CI
Closed Merger/Acquisition Transaction – Target: Chadiostech Co., Ltd.; Buyer(s): Da Vinci Capital Management Ltd., The European Bank for Reconstruction and Development, Investment Arm; Seller(s): CHA Biotech Co., Ltd., Kyunghee Industry Co. Ltd., Sungkwang Medical Foundation, Endowment Arm; Transaction Size: KRW23503.27 mm
CI
The Da Vinci CIS Private Sector Growth Fund (Fund I), Da Vinci Eurasian Financial Infrastructure Fund (Fund II) and Da Vinci No. 3 Investment Fund (Fund III) of Da Vinci Capital Management Ltd. and The European Bank for Reconstruction and Development, Investment Arm, Chang-Mi Bin, Jung-Seok Oh and Jung-Seok Kang entered into a contract to acquire 22.66% stake in Chadiostech Co., Ltd. from Gwang-Yeol Cha, 8 other individuals, CHA Biotech Co., Ltd., Kyunghee Indus
CI
CHA Healthcare Operation Co., Ltd. cancelled the acquisition of Cha Medical Service Co., Ltd. from CHA Bio&Diostech Inc. and others.
CI
CHA-Meditech Co., Ltd. acquired CHA-BioMed Co. Ltd from CHA Bio&Diostech Inc. and other sellers.
CI
CHA Healthcare Operation Co., Ltd. agreed to acquire Cha Medical Service Co., Ltd. from CHA Bio&Diostech Inc. and others.
CI
CHA Bio & Diostech Co., Ltd. completed the spin-off of camera lens and optical science business division for KRW 140 billion
CI
CHA Bio & Diostech Co., Ltd. agreed to spin-off camera lens and optical science business division.
CI
Cha Bio&Diostech Files Investigational New Drug with Korean FDA for PLX Cells
CI
Pluristem Therapeutics, Inc. Enters into Exclusive License and Commercialization Agreement with CHA Bio & Diostech Co., Ltd
CI
Pluristem Ltd. Enters Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and Commercialization of PLX Cells for the Treatment of CLI and IC in South Korea
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A085660 Stock
  4. News Chabiotech Co.,Ltd.
  5. Highlights